MedTrace Logo

Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus

NCT01126255 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2022-04-01

No results posted yet for this study

Summary

This is a randomized trial comparing progesterone with conventional clobetasol propionate in patients with vulvar lichen sclerosus.

Conditions

  • Vulvar Lichen Sclerosus

Interventions

DRUG

Clobetasol propionate 0.05%

Topical application, once daily about 2 g, during 12 weeks

DRUG

Progesterone 8%

Topical application, once daily about 2 g, during 12 weeks

Sponsors & Collaborators

  • University of Bern

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Andreas Guenthert, Prof. Dr. med.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01126255 on ClinicalTrials.gov